Late Phase Brochure

The success of a new product is judged by more than its promising clinical trial results. It needs to achieve its commercial objectives to justify initial investment. Chiltern Late Phase has focus in both local and national studies as well as large global programs. For example, Chiltern is currently performing registries from 100 patients to over 20,000 patients in a global setting.